- Pliant Therapeutics to Participate in Upcoming Investor Events
- Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
- Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
- Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
- Pliant Therapeutics to Participate in Upcoming Investor Conferences
- Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
- Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
- Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
- Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
- Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.90 |
---|---|
High | 10.90 |
Low | 10.60 |
Bid | 10.90 |
Offer | 11.30 |
Previous close | 10.90 |
Average volume | 0.00 |
---|---|
Shares outstanding | 60.24m |
Free float | 56.20m |
P/E (TTM) | -- |
Market cap | 715.64m USD |
EPS (TTM) | -2.75 USD |
Data delayed at least 15 minutes, as of Apr 25 2024.
More ▼